Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Affiliation
Alimentary Pharmabiotic Centre and Department of Psychiatry, Cork University, Hospital, Wilton, Cork, Ireland.Issue Date
2012-02-03T15:04:47ZMeSH
AdultAnalysis of Variance
Antidepressive Agents/*therapeutic use
Cytokines/*blood
Depressive Disorder, Major/*blood/drug therapy
Drug Resistance/*physiology
Enzyme-Linked Immunosorbent Assay/methods
Female
Humans
Male
Middle Aged
Psychiatric Status Rating Scales
Serotonin Uptake Inhibitors/*therapeutic use
Metadata
Show full item recordCitation
J Psychiatr Res. 2007 Apr-Jun;41(3-4):326-31. Epub 2006 Jul 25.Journal
Journal of psychiatric researchDOI
10.1016/j.jpsychires.2006.05.013PubMed ID
16870211Abstract
OBJECTIVE: Approximately 30% of patients with depression fail to respond to a selective serotonin reuptake inhibitor (SSRI). Few studies have attempted to define these patients from a biological perspective. Studies suggest that overall patients with depression show increased production of proinflammatory cytokines. We examined pro- and anti-inflammatory cytokine levels in patients who were SSRI resistant. METHODS: Plasma concentrations of IL-6, IL-8, IL-10, TNF-alpha and sIL-6R were measured with enzyme linked immunosorbent assays (ELISA) in DSM-1V major depressives who were SSRI resistant, in formerly SSRI resistant patients currently euthymic and in healthy controls. RESULTS: Patients with SSRI-resistant depression had significantly higher production of the pro-inflammatory cytokines IL-6 (p=0.01) and TNF-alpha (p=0.004) compared to normal controls. Euthymic patients who were formerly SSRI resistant had proinflammatory cytokine levels which were similar to the healthy subject group. Anti-inflammatory cytokine levels did not differ across the 3 groups. CONCLUSION: Suppression of proinflammatory cytokines does not occur in depressed patients who fail to respond to SSRIs and is necessary for clinical recovery.Language
engISSN
0022-3956 (Print)0022-3956 (Linking)
ae974a485f413a2113503eed53cd6c53
10.1016/j.jpsychires.2006.05.013
Scopus Count
Collections
Related articles
- Variations in circulating cytokine levels during 52 week course of treatment with SSRI for major depressive disorder.
- Authors: Hernández ME, Mendieta D, Martínez-Fong D, Loría F, Moreno J, Estrada I, Bojalil R, Pavón L
- Issue date: 2008 Dec
- The Relationship Between Plasma Cytokine Levels and Response to Selective Serotonin Reuptake Inhibitor Treatment in Children and Adolescents with Depression and/or Anxiety Disorders.
- Authors: Amitai M, Taler M, Carmel M, Michaelovsky E, Eilat T, Yablonski M, Orpaz N, Chen A, Apter A, Weizman A, Fennig S
- Issue date: 2016 Oct
- IL-6 levels decrease with SSRI treatment in patients with major depression.
- Authors: Basterzi AD, Aydemir C, Kisa C, Aksaray S, Tuzer V, Yazici K, Göka E
- Issue date: 2005 Oct
- Pro-inflammatory cytokines as predictors of antidepressant effects of exercise in major depressive disorder.
- Authors: Rethorst CD, Toups MS, Greer TL, Nakonezny PA, Carmody TJ, Grannemann BD, Huebinger RM, Barber RC, Trivedi MH
- Issue date: 2013 Oct
- Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression.
- Authors: Yoshimura R, Hori H, Ikenouchi-Sugita A, Umene-Nakano W, Ueda N, Nakamura J
- Issue date: 2009 Jun 15